Erratum: Lowversus standard-dose alteplase for ischemic strokes within 4.5 hours: A comparative effectiveness and safety study (Stroke (2015) 46 (2541-2548) DOI: 10.1161/STROKEAHA.115.010180);Low-Versus Standard-Dose Alteplase for Ischemic Strokes Within 4.5 Hours: A Comparative Effectiveness and Safety Study

Stroke

Volumn 46, Issue 9, 2015, Pages 2541-2548

  Kim, Beom Joon ^a   Han, Moon Ku ^a   Park, Tai Hwan ^b   Park, Sang Soon ^b   Lee, Kyung Bok ^c   Lee, Byung Chul ^d   Yu, Kyung Ho ^d   Oh, Mi Sun ^d   Cha, Jae Kwan ^e   Kim, Dae Hyun ^e   Lee, Jun ^f   Lee, Soo Joo ^g   Ko, Youngchai ^g   Park, Jong Moo ^h   Kang, Kyusik ^h   Cho, Yong Jin ⁱ   Hong, Keun Sik ⁱ   Kim, Joon Tae ^j   Choi, Jay Chol ^k   Kim, Dong Eog ^l   Shin, Dong Ick ^m   Kim, Wook Joo ⁿ   Lee, Juneyoung ^o   Lee, Ji Sung ^p   Yoon, Byung Woo ^q   Gorelick, Philip B ^r   Bae, Hee Joon ^a   more..

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul Medical Center   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

^d Hallym University   (South Korea)

^e Dong A University College of Medicine   (South Korea)

^f Yeungnam University Hospital   (South Korea)

^g Eulji University School of Medicine   (South Korea)

^h Eulji General Hospital   (South Korea)

ⁱ Inje University   (South Korea)

^j Chonnam National University Medical School   (South Korea)

^k Jeju National University   (South Korea)

^l Dongguk University Ilsan Hospital   (South Korea)

^m Chungbuk National University Hospital   (South Korea)

ⁿ University of Ulsan College of Medicine   (South Korea)

^o Korea University College of Medicine   (South Korea)

^p Asan Medical Center   (South Korea)

^q Seoul National University Hospital   (South Korea)

^r MICHIGAN STATE UNIVERSITY   (United States)

more..

Author keywords

acute ischemic stroke; hemorrhage; low dose tPA; thrombolysis; tissue type plasminogen activator

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; DATA BASE; DISEASE REGISTRY; DRUG DOSE COMPARISON; FEMALE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANKIN SCALE; RECANALIZATION; STROKE PATIENT; CLINICAL TRIAL; COMPARATIVE STUDY; FIBRINOLYTIC THERAPY; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; REGISTER; SEVERITY OF ILLNESS INDEX; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); REGISTRIES; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84940398535     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STR.0000000000000080     Document Type: Erratum

References (32)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New Engl J Med. 1995;333:1581-1587. doi: 10.1056/NEJM199512143332401.
2. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9:167-176. doi: 10.1016/S1474-4422(09)70340-0.
3. Ueshima S, Matsuo O. The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians. Thromb Haemost. 2002;87:544-546.
4. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al; Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006;37:1810-1815. doi: 10.1161/01. STR.0000227191.01792.e3.
5. Mori E, Minematsu K, Nakagawara J, Yamaguchi T, Sasaki M, Hirano T; Japan Alteplase Clinical Trial II Group. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke. 2010;41:461-465. doi: 10.1161/STROKEAHA.109.573477.
6. Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, et al; J-MARS Investigators. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke. 2010;41:1984-1989. doi: 10.1161/STROKEAHA.110.589606.
7. Toyoda K, Koga M, Naganuma M, Shiokawa Y, Nakagawara J, Furui E, et al; Stroke Acute Management with Urgent Risk-factor Assessment and Improvement Study Investigators. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Stroke. 2009;40:3591-3595. doi: 10.1161/STROKEAHA.109.562991.
8. Chao AC, Hsu HY, Chung CP, Liu CH, Chen CH, Teng MM, et al; Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study Group. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study. Stroke. 2010;41:885-890. doi: 10.1161/STROKEAHA.109.575605.
9. Ng KW, Sharma VK. Low-dose versus standard-dose tissue plasminogen activator for intravenous thrombolysis in Asian acute ischemic stroke patients. Stroke. 2010;41:e545-e546, author reply e547. doi: 10.1161/STROKEAHA.110.582403.
10. Salam KA, Ummer K, Kumar VG, Noone ML, Laila A, Ragini J. Intravenous thrombolysis for acute ischemic stroke: the Malabar experience 2003 to 2008. J Clin Neurosci. 2009;16:1276-1278. doi: 10.1016/j. jocn.2009.01.004.
11. Sharma VK, Tsivgoulis G, Tan JH, Wong LY, Ong BK, Chan BP, et al. Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore. J Stroke Cerebrovasc Dis. 2010;19:424-430. doi: 10.1016/j.jstrokecerebrovasdis.2009.07.015.
12. Wang Y, Liao X, Zhao X, Wang DZ, Wang C, Nguyen-Huynh MN, et al; China National Stroke Registry Investigators. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke. 2011;42:1658-1664. doi: 10.1161/STROKEAHA.110.604249.
13. Chao AC, Liu CK, Chen CH, Lin HJ, Liu CH, Jeng JS, et al; Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study Group. Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients. Stroke. 2014;45:2359-2365. doi: 10.1161/STROKEAHA.114.005245.
14. Liao X, Wang Y, Pan Y, Wang C, Zhao X, Wang DZ, et al; Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China Investigators. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses. Stroke. 2014;45:2354-2358. doi: 10.1161/STROKEAHA.114.005989.
15. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11-20. doi: 10.1056/NEJMoa1411587.
16. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009-1018. doi: 10.1056/NEJMoa1414792.
17. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019-1030. doi: 10.1056/NEJMoa1414905.
18. Bufalino VJ, Masoudi FA, Stranne SK, Horton K, Albert NM, Beam C, et al; American Heart Association Advocacy Coordinating Committee. The American Heart Association's recommendations for expanding the applications of existing and future clinical registries: a policy statement from the American Heart Association. Circulation. 2011;123:2167-2179. doi: 10.1161/CIR.0b013e3182181529.
19. Kim BJ, Park JM, Kang K, Lee SJ, Ko Y, Kim JG, et al. Case characteristics, hyperacute treatment, and outcome information from the clinical research center for stroke-fifth division registry in South Korea. J Stroke. 2015;17:38-53. doi: 10.5853/jos.2015.17.1.38.
20. Kim BJ, Han MK, Park TH, Park SS, Lee KB, Lee BC, et al; CRCS-5 investigators. Current status of acute stroke management in Korea: a report on a multicenter, comprehensive acute stroke registry. Int J Stroke. 2014;9:514-518. doi: 10.1111/ijs.12199.
21. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947. doi: 10.1161/STR.0b013e318284056a.
22. Raghunathan TE, Lepkowski JM, Van Hoewyk J, Solenberger P. A multivariate technique for multiply imputing missing values using a sequence of regression models. Survey Methodol. 2001;27:85-96.
23. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
24. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550-560.
25. Haviland A, Nagin DS, Rosenbaum PR. Combining propensity score matching and group-based trajectory analysis in an observational study. Psychol Methods. 2007;12:247-267. doi: 10.1037/1082-989X.12.3.247.
26. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561-570.
27. Ko Y, Lee S, Chung JW, Han MK, Park JM, Kang K, et al. MRI-based Algorithm for Acute Ischemic Stroke Subtype Classification. J Stroke. 2014;16:161-172. doi: 10.5853/jos.2014.16.3.161.
28. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282. doi: 10.1016/S0140-6736(07)60149-4.
29. Huang Y, Sharma VK, Robinson T, Lindley RI, Chen X, Kim JS, et al; ENCHANTED investigators. Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2×2 quasi-factorial randomized controlled trial of low-vs. standarddose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment. Int J Stroke. 2015;10:778-788. doi: 10.1111/ijs.12486.
30. Harston GW, Sutherland BA, Kennedy J, Buchan AM. The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity. J Cereb Blood Flow Metab. 2010;30:1804-1816. doi: 10.1038/jcbfm.2010.149.
31. Appireddy RM, Demchuk AM, Goyal M, Menon BK, Eesa M, Choi P, et al. Endovascular therapy for ischemic stroke. J Clin Neurol. 2015;11:1-8. doi: 10.3988/jcn.2015.11.1.1.
32. Mori E. Safety and efficacy of 0.6 mg/kg rt-PA: optimum rt-PA dose revisited. Ann N Y Acad Sci. 2012;1268: 108-112. 10.1111/j.1749-6632.2012.06689.x.